Pioglitazone HCl solid dispersion formulations combining five polymers to improve dissolving profile

Abstract

Many medicines with therapeutic promise are never developed because of their low water solubility. There
are a variety of approaches that have been taken to increase the solubility of medications in water. Poorly
water-soluble pharmaceuticals may have their solubility and, by extension, their bioavailability enhanced
by the use of solid dispersion. The purpose of this research was to examine the influence of different
polymers on the solubility of pioglitazone HCl by preparing solid dispersions of the drug using PEG 6000,
PVP, Poloxamer 407, Eudragit EPO, and HPMC. Pioglitazone HCl solid dispersion was made by solvent
evaporation technique. The yield, drug content, FT-IR spectrum, and in vitro dissolution investigations of
the solid dispersions were analyzed. The reliability of the experiment is guaranteed by the histogram of
responses and the descriptive statistics of responses. The findings obtained demonstrate that the dissolving
profile of Pioglitazone HCl solid dispersion was greatly improved. After 30 minutes, the release of
Pioglitazone HCl from solid dispersions including PVP K30, HPMC, PEG 6000, Eudragit EPO, and
Poloxamer 407 is 75%, 74%, 100%, 50%, and 62%, respectively, whereas the release from Pioglitazone
HCl alone is only 12.05%. The findings suggest that the solid dispersion approach is a viable option for
enhancing the dissolving profile of weakly water soluble drugs.